Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1183279

	registered interest
	date	06/03/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Health Services: Coronavirus
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care what steps he is taking to support NHS staff in the event of increased patient admissions as a result of covid-19.
	tabling member constituency	Erith and Thamesmead
	tabling member printed	Abena Oppong-Asare
	uin	26182
	answer	answer is ministerial correction date of answer 16/03/2020 answer text <p>The National Health Service will be given all the resources it needs to respond to this virus and keep the public safe.</p><p>The NHS is scaling up intensive care beds, whilst NHS England is looking at NHS organisations’ critical care capacity - including the availability of additional facilities operated by independent sector providers. They are also making sure that they have as much ventilation equipment as possible and, crucially, the skilled and trained people to use it.</p><p>The Health and Wellbeing Framework sets out the standards for what NHS organisations need to do to support staff to feel well, healthy and happy at work. It sets out clear actionable steps and provides guidance for organisations to develop and deliver a staff health and wellbeing plan. The link for this guidance can be found at the following link:</p><p><a href="https://www.nhsemployers.org/retention-and-staff-experience/health-and-wellbeing" target="_blank">https://www.nhsemployers.org/retention-and-staff-experience/health-and-wellbeing</a></p><p> </p> answering member constituency Charnwood answering member printed Edward Argar question first answered 16/03/2020 11:51:39 answering member 4362 label Biography information for Edward Argar
	tabling member	4820 label Biography information for Abena Oppong-Asare

1019373

	registered interest
	date	03/12/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Clinical Waste
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will estimate how much (a) anatomical and (b) cytotoxic waste the NHS (i) produced in (A) 2017 and (B) 2018 and (ii) will produce in (A) 2025 and (B) 2030.
	tabling member constituency	Windsor
	tabling member printed	Adam Afriyie
	uin	198202
	answer	answer is ministerial correction date of answer 11/12/2018 answer text <p>The following table shows the information that NHS Improvement hold for the waste produced by the National Health Service in 2017 and 2018. NHS Improvement does not currently hold a breakdown of waste into anatomical and cytotoxic.</p><p> </p><p>The data contained within this table relates only to England. As waste disposal is a devolved matter, devolved administrations should be contacted for figures in those nations.</p><p> </p><p>NHS Improvement and the Environment Agency are not in a position to estimate anatomical and cytotoxic waste figures in 2025 and 2030.</p><p> </p><table><tbody><tr><td><p> </p></td><td><p>Sum of Landfill disposal volume (Tonnes)</p></td><td><p>Sum of Incineration disposal volume (Tonnes)</p></td><td><p>Sum of Waste recycling volume (Tonnes)</p></td><td><p>Sum of Other recovery volume (Tonnes)</p></td></tr><tr><td><p>2017-18</p></td><td><p>58,152</p></td><td><p>74,730</p></td><td><p>107,848</p></td><td><p>183,502</p></td></tr><tr><td><p>2016-17</p></td><td><p>88,594</p></td><td><p>148,424</p></td><td><p>137,442</p></td><td><p>216,495</p></td></tr></tbody></table> answering member constituency Wimbledon answering member printed Stephen Hammond question first answered 11/12/2018 16:42:46 answering member 1585 label Biography information for Stephen Hammond
	tabling member	1586 label Biography information for Adam Afriyie

1056741

	registered interest
	date	07/02/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Electronic Cigarettes
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what progress he has made on implementing the recommendations accepted by the Government in its response to the Science and Technology Committee's Seventh Report of Session 2017-19 on E-cigarettes, HC505.
	tabling member constituency	Windsor
	tabling member printed	Adam Afriyie
	uin	218245
	answer	answer is ministerial correction date of answer 15/02/2019 answer text <p>The Government published its response to the Science and Technology Committee on the 10 December 2018. Good progress is being made on implementing the report’s recommendations: for example, Public Health England will publish its latest annual evidence review on e-cigarettes by the end of March 2019 and NHS England is developing guidance on e-cigarettes for mental health trusts. The Department will continue to monitor progress as part of its monitoring of the delivery of the Tobacco Control Plan for England.</p><p> </p><p>The Government believes in proportionate regulation of e-cigarettes, recognising that they are not risk-free. Through the European Union Tobacco Products Directive 2014/40/EU (TPD), transposed into United Kingdom law by the UK Tobacco and Related Products Regulations 2016 (TRPR), we have introduced measures to regulate e-cigarettes to reduce the risk of harm to children, protect against any risk of renormalisation of tobacco use, provide assurance on relative safety for users, and give businesses legal certainty. This has enabled the UK to implement appropriate standards for products whilst allowing smokers to move to e-cigarettes should they wish.</p><p> </p><p>While the UK Government is a member of the EU it will continue to comply with the requirements of the EU’s TPD. The Government has made a commitment to review the TRPR by May 2021 to consider its regulatory impact. In addition, as announced in the Tobacco Control Plan the Government will review where the UK’s exit from the EU offers us opportunities to re-appraise current regulation to ensure this continues to protect the nation’s health.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 218246 question first answered 15/02/2019 11:10:04 answering member 4067 label Biography information for Steve Brine
	tabling member	1586 label Biography information for Adam Afriyie

1056744

	registered interest
	date	07/02/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Electronic Cigarettes
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, with reference to the Seventh Report of Session 2017-19 of the Science and Technology Committee on E-cigarettes, HC505, what steps he has taken to ensure that the regulatory system for e-cigarettes is risk-proportionate.
	tabling member constituency	Windsor
	tabling member printed	Adam Afriyie
	uin	218246
	answer	answer is ministerial correction date of answer 15/02/2019 answer text <p>The Government published its response to the Science and Technology Committee on the 10 December 2018. Good progress is being made on implementing the report’s recommendations: for example, Public Health England will publish its latest annual evidence review on e-cigarettes by the end of March 2019 and NHS England is developing guidance on e-cigarettes for mental health trusts. The Department will continue to monitor progress as part of its monitoring of the delivery of the Tobacco Control Plan for England.</p><p> </p><p>The Government believes in proportionate regulation of e-cigarettes, recognising that they are not risk-free. Through the European Union Tobacco Products Directive 2014/40/EU (TPD), transposed into United Kingdom law by the UK Tobacco and Related Products Regulations 2016 (TRPR), we have introduced measures to regulate e-cigarettes to reduce the risk of harm to children, protect against any risk of renormalisation of tobacco use, provide assurance on relative safety for users, and give businesses legal certainty. This has enabled the UK to implement appropriate standards for products whilst allowing smokers to move to e-cigarettes should they wish.</p><p> </p><p>While the UK Government is a member of the EU it will continue to comply with the requirements of the EU’s TPD. The Government has made a commitment to review the TRPR by May 2021 to consider its regulatory impact. In addition, as announced in the Tobacco Control Plan the Government will review where the UK’s exit from the EU offers us opportunities to re-appraise current regulation to ensure this continues to protect the nation’s health.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 218245 question first answered 15/02/2019 11:10:04 answering member 4067 label Biography information for Steve Brine
	tabling member	1586 label Biography information for Adam Afriyie

1126877

	registered interest
	date	15/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Cybersecurity
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how much the National Health Service spent on cyber security in each of the last five years.
	tabling member constituency	Windsor
	tabling member printed	Adam Afriyie
	uin	254785
	answer	answer is ministerial correction date of answer 24/05/2019 answer text <p>The information requested on cyber spending covers sensitive detail about cyber security investment for the National Health Service. In this instance, releasing this information at the level of any annual breakdown may assist in determining the effectiveness of detecting cyber-attacks on the NHS, and could compromise measures to protect NHS IT systems, leaving them vulnerable to future cyber-attacks.</p><p>However, in total, over £250 million will have been invested nationally to improve the cyber security of the health and care system between 2016 and 2021. This excludes both investment by local organisations, and wider national IT investment which supports better security such as Microsoft licensing for NHS organisations.</p><p>Regarding the steps taken to defend against cyber attacks on the NHS, the active cyber defence of NHS organisations is a local responsibility for each organisation to carry out. However, there is national support and practical guidance available to NHS organisations which is primarily delivered by NHS Digital but supported and prioritised for the highest risk organisations by NHS England and the Department. In the event of national-scale incidents that affect many health and care organisations, NHS Digital plays a vital role in coordinating and ensuring appropriate technical remediation, as part of the wider cross-system cyber security response led by the Department.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price grouped question UIN 254786 question first answered 24/05/2019 12:33:05 answering member 4065 label Biography information for Dame Jackie Doyle-Price
	tabling member	1586 label Biography information for Adam Afriyie

1126878

	registered interest
	date	15/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Cybercrime
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps he has taken to ensure that NHS England is prepared to defend the NHS against cyber attacks.
	tabling member constituency	Windsor
	tabling member printed	Adam Afriyie
	uin	254786
	answer	answer is ministerial correction date of answer 24/05/2019 answer text <p>The information requested on cyber spending covers sensitive detail about cyber security investment for the National Health Service. In this instance, releasing this information at the level of any annual breakdown may assist in determining the effectiveness of detecting cyber-attacks on the NHS, and could compromise measures to protect NHS IT systems, leaving them vulnerable to future cyber-attacks.</p><p>However, in total, over £250 million will have been invested nationally to improve the cyber security of the health and care system between 2016 and 2021. This excludes both investment by local organisations, and wider national IT investment which supports better security such as Microsoft licensing for NHS organisations.</p><p>Regarding the steps taken to defend against cyber attacks on the NHS, the active cyber defence of NHS organisations is a local responsibility for each organisation to carry out. However, there is national support and practical guidance available to NHS organisations which is primarily delivered by NHS Digital but supported and prioritised for the highest risk organisations by NHS England and the Department. In the event of national-scale incidents that affect many health and care organisations, NHS Digital plays a vital role in coordinating and ensuring appropriate technical remediation, as part of the wider cross-system cyber security response led by the Department.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price grouped question UIN 254785 question first answered 24/05/2019 12:33:05 answering member 4065 label Biography information for Dame Jackie Doyle-Price
	tabling member	1586 label Biography information for Adam Afriyie

1170391

	registered interest
	date	13/01/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Mental Health Services: Children and Young People
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether his Department is on course to meet its 2024 target of a maximum four-week waiting time for children and young people who are referred to a mental health specialist.
	tabling member constituency	Windsor
	tabling member printed	Adam Afriyie
	uin	2459
	answer	answer is ministerial correction date of answer 21/01/2020 answer text <p>NHS England is currently working nationally with 12 pilot sites to test the feasibility of delivering a four-week waiting time for access to National Health Service mental health support. Delivering and maintaining a waiting time across the large and complex children and young people’s mental health pathway is a challenge, and we are proceeding carefully so as not to establish any perverse incentives.</p><p> </p><p>The pilots will test not only what it takes to achieve and maintain a four-week waiting time, but also how best to define and measure this access to specialist children and young people’s mental health services.</p><p> </p><p>The agreed pilots end in 2020/21. Results will then be evaluated. The Department and NHS England will consider the results of the evaluation and will look at its implications for the development and rollout of access and waiting time standards for all children and young people who need specialist mental health services.</p><p> </p><p> </p><p> </p> answering member constituency Mid Bedfordshire answering member printed Ms Nadine Dorries question first answered 21/01/2020 14:30:58 answering member 1481 label Biography information for Ms Nadine Dorries
	tabling member	1586 label Biography information for Adam Afriyie

1054826

	registered interest
	date	04/02/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Yellow Fever: Vaccination
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will make representations to Sanofi Pasteur on undertaking new research into the risks of adverse events, including psychosis, from using the vaccine Stamaril.
	tabling member constituency	Gravesham
	tabling member printed	Adam Holloway
	uin	216210
	answer	answer is ministerial correction date of answer 12/02/2019 answer text <p>As with all vaccines and medicines, the Medicines and Healthcare products Regulatory Agency (MHRA) closely monitors the safety of Stamaril yellow fever vaccine. The MHRA takes advice from the Government's independent scientific advisory body, the Commission on Human Medicines, when evaluating the risks and benefits of medicines and vaccines.</p><p> </p><p>The Marketing Authorisation Holder for Stamaril, Sanofi Pasteur, has statutory obligations to continuously monitor the safety, and balance of benefits and risks, of the vaccine.</p><p> </p><p>The potential risks of Stamaril are described in the prescribing information, the Summary of Product Characteristics, and the information for vaccine recipients, the Patient Information Leaflet. A recognised, very rare risk of Stamaril vaccine is Yellow Fever Vaccine-Associated Neurotropic Disease, known as YEL-AND. Whilst the symptoms of YEL-AND can include confusion and acute focal neurological deficits (e.g. affecting motor co-ordination), this is not typically associated with psychosis or other long-term psychiatric disorders.</p><p> </p><p>Further to other recent reports of serious suspected adverse reactions in United Kingdom travellers, the MHRA is in the process of further reviewing the balance of benefits and risks of Yellow Fever vaccine, which will include an analysis of neuropsychiatric events.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price grouped question UIN 216211 216213 question first answered 12/02/2019 17:04:11 answering member 4065 label Biography information for Dame Jackie Doyle-Price
	tabling member	1522 label Biography information for Adam Holloway

1054828

	registered interest
	date	04/02/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Yellow Fever: Vaccination
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what representations he has made to Sanofi Pasteur on ensuring that new technology is developed to eliminate the risks of adverse events, including psychosis, from the use of the vaccine Stamaril.
	tabling member constituency	Gravesham
	tabling member printed	Adam Holloway
	uin	216211
	answer	answer is ministerial correction date of answer 12/02/2019 answer text <p>As with all vaccines and medicines, the Medicines and Healthcare products Regulatory Agency (MHRA) closely monitors the safety of Stamaril yellow fever vaccine. The MHRA takes advice from the Government's independent scientific advisory body, the Commission on Human Medicines, when evaluating the risks and benefits of medicines and vaccines.</p><p> </p><p>The Marketing Authorisation Holder for Stamaril, Sanofi Pasteur, has statutory obligations to continuously monitor the safety, and balance of benefits and risks, of the vaccine.</p><p> </p><p>The potential risks of Stamaril are described in the prescribing information, the Summary of Product Characteristics, and the information for vaccine recipients, the Patient Information Leaflet. A recognised, very rare risk of Stamaril vaccine is Yellow Fever Vaccine-Associated Neurotropic Disease, known as YEL-AND. Whilst the symptoms of YEL-AND can include confusion and acute focal neurological deficits (e.g. affecting motor co-ordination), this is not typically associated with psychosis or other long-term psychiatric disorders.</p><p> </p><p>Further to other recent reports of serious suspected adverse reactions in United Kingdom travellers, the MHRA is in the process of further reviewing the balance of benefits and risks of Yellow Fever vaccine, which will include an analysis of neuropsychiatric events.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price grouped question UIN 216210 216213 question first answered 12/02/2019 17:04:11 answering member 4065 label Biography information for Dame Jackie Doyle-Price
	tabling member	1522 label Biography information for Adam Holloway

1054829

	registered interest
	date	04/02/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Yellow Fever: Vaccination
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will commission research into new vaccines for yellow fever in the event that Sanofi Pasteur does not undertake research into its yellow fever vaccine.
	tabling member constituency	Gravesham
	tabling member printed	Adam Holloway
	uin	216212
	answer	answer is ministerial correction date of answer 12/02/2019 answer text <p>The Department’s National Institute for Health Research (NIHR) welcomes funding applications for research into any aspect of human health, including the development of cheaper vaccines. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money and scientific quality. In all disease areas, the amount of NIHR funding depends on the volume and quality of scientific activity.</p><p> </p><p>The NIHR and the Medical Research Council both have a wide portfolio of research activity in vaccines which cover clinical trials for new vaccines, new technologies, ways of improving uptake and cost effectiveness.</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 12/02/2019 16:24:27 answering member 4008 label Biography information for Dame Caroline Dinenage
	tabling member	1522 label Biography information for Adam Holloway